Non-coding mutations in congenital hyperinsulinism: deciphering the role of gene dysregulation in human disease
In plain English
AI plain-English summaryA single DNA typo in a non-coding region can switch on a gene that should stay silent in insulin-making cells, triggering dangerously low blood sugar in newborns. This matters because congenital hyperinsulinism—where the pancreas pumps out too much insulin—can cause brain damage if not caught early. Current treatments are limited, and many patients still need their pancreas partly removed. The problem is that most genetic studies focus on protein-coding genes, but the real culprits may lie in the vast non-coding stretches of DNA that control when and where genes turn on. The researcher has already found one such mutation that reactivates *HK1*, a gene normally shut off in beta-cells. Now, using a unique cohort of ~2000 patients with no known cause, they will scan for similar regulatory glitches. If successful, this work could reveal new drug targets for hyperinsulinism—perhaps molecules that re-silence these rogue genes without surgery. More broadly, it will demonstrate how non-coding mutations drive disease, opening a new avenue for diagnosing and treating other monogenic conditions where coding mutations have come up empty. This is fundamental science with a clear clinical horizon.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Senior Research FellowshipPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know